FindTrial
Sign In

Combination of dexamethasone, pegaspargase, etoposide, gemcitabine (DPEG) in the treatment of relapsed/refractory or advanced NK/T-cell lymphoma: a prospective, single centre, single arm, phase 2 study

Combination of dexamethasone, pegaspargase, etoposide, gemcitabine (DPEG) in the treatment of relapsed/refractory or advanced NK/T-cell lymphoma: a prospective, single centre, single arm, phase 2 study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000028974
Enrollment
Unknown
Registered
2020-01-10
Start date
2020-01-14
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NK/T-cell lymphoma

Interventions

study group:DGEP therapy

Sponsors

Beijing Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. pathology confirmed the diagnosis of ENKTL; 2. stage III-IV or relapsed/refractory Stage I-II disease; 3. evaluable lesions; 4. supposed to be alive for at least 3 months; 5. aged 18-75 years; 6. ECOG=0-2; 7. no effective chemotherapy within 3 weeks before enrollment except for steroids alone; 8. acceptable liver/kidney function.

Exclusion criteria

Exclusion criteria: 1. CNS involvment; 2. pregnancy; 3. unwilling to be birth-control; 4. allergic to study drugs; 5. uncontrolled infection.

Design outcomes

Primary

MeasureTime frame
2-year PFS;—

Secondary

MeasureTime frame
2-year OS;complete remission rate;overall remission rate;safety profiles;—

Countries

China

Contacts

Public ContactJing-wen Wang

Beijing Tongren Hospital

shanibetty@126.com+86 15801116688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026